228 related articles for article (PubMed ID: 28960191)
41. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1.
Calvo KR; Sykes DB; Pasillas MP; Kamps MP
Oncogene; 2002 Jun; 21(27):4247-56. PubMed ID: 12082612
[TBL] [Abstract][Full Text] [Related]
42. MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.
Yokoyama T; Nakatake M; Kuwata T; Couzinet A; Goitsuka R; Tsutsumi S; Aburatani H; Valk PJ; Delwel R; Nakamura T
J Clin Invest; 2016 May; 126(5):1664-78. PubMed ID: 27018596
[TBL] [Abstract][Full Text] [Related]
43. MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice.
Kawagoe H; Grosveld GC
Blood; 2005 Dec; 106(13):4278-86. PubMed ID: 16081688
[TBL] [Abstract][Full Text] [Related]
44. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
45. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia.
Thorsteinsdottir U; Kroon E; Jerome L; Blasi F; Sauvageau G
Mol Cell Biol; 2001 Jan; 21(1):224-34. PubMed ID: 11113197
[TBL] [Abstract][Full Text] [Related]
46. Identification of E74-like factor 1 (ELF1) as a transcriptional regulator of the Hox cofactor MEIS1.
Xiang P; Lo C; Argiropoulos B; Lai CB; Rouhi A; Imren S; Jiang X; Mager D; Humphries RK
Exp Hematol; 2010 Sep; 38(9):798-8, 808.e1-2. PubMed ID: 20600580
[TBL] [Abstract][Full Text] [Related]
47. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
[TBL] [Abstract][Full Text] [Related]
48. HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis.
Hu YL; Fong S; Ferrell C; Largman C; Shen WF
Mol Cell Biol; 2009 Sep; 29(18):5181-92. PubMed ID: 19620287
[TBL] [Abstract][Full Text] [Related]
49. Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc.
Garcia-Cuellar MP; Prinz A; Slany RK
Haematologica; 2022 Nov; 107(11):2601-2616. PubMed ID: 35546301
[TBL] [Abstract][Full Text] [Related]
50. Identification and characterization of Hoxa9 binding sites in hematopoietic cells.
Huang Y; Sitwala K; Bronstein J; Sanders D; Dandekar M; Collins C; Robertson G; MacDonald J; Cezard T; Bilenky M; Thiessen N; Zhao Y; Zeng T; Hirst M; Hero A; Jones S; Hess JL
Blood; 2012 Jan; 119(2):388-98. PubMed ID: 22072553
[TBL] [Abstract][Full Text] [Related]
51.
Wang W; Li H; Huang M; Wang X; Li W; Qian X; Jing L
Open Biol; 2022 Oct; 12(10):220172. PubMed ID: 36285442
[No Abstract] [Full Text] [Related]
52. Distal regulation of c-myb expression during IL-6-induced differentiation in murine myeloid progenitor M1 cells.
Zhang J; Han B; Li X; Bies J; Jiang P; Koller RP; Wolff L
Cell Death Dis; 2016 Sep; 7(9):e2364. PubMed ID: 27607579
[TBL] [Abstract][Full Text] [Related]
53. MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
Meriç N; Albayrak E; Gülbaş Z; Kocabaş F
Leuk Lymphoma; 2024 Feb; 65(2):187-198. PubMed ID: 37902585
[TBL] [Abstract][Full Text] [Related]
54. MEIS1, PREP1, and PBX4 are differentially expressed in acute lymphoblastic leukemia: association of MEIS1 expression with higher proliferation and chemotherapy resistance.
Rosales-Aviña JA; Torres-Flores J; Aguilar-Lemarroy A; Gurrola-Díaz C; Hernández-Flores G; Ortiz-Lazareno PC; Lerma-Díaz JM; de Celis R; González-Ramella Ó; Barrera-Chaires E; Bravo-Cuellar A; Jave-Suárez LF
J Exp Clin Cancer Res; 2011 Dec; 30(1):112. PubMed ID: 22185299
[TBL] [Abstract][Full Text] [Related]
55. Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3.
Argiropoulos B; Palmqvist L; Yung E; Kuchenbauer F; Heuser M; Sly LM; Wan A; Krystal G; Humphries RK
Exp Hematol; 2008 Jul; 36(7):845-59. PubMed ID: 18375036
[TBL] [Abstract][Full Text] [Related]
56. Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory.
Stahlhut M; Ha TC; Takmakova E; Morgan MA; Schwarzer A; Schaudien D; Eder M; Schambach A; Kustikova OS
Sci Rep; 2021 Mar; 11(1):5294. PubMed ID: 33674652
[TBL] [Abstract][Full Text] [Related]
57. C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis.
Collins C; Wang J; Miao H; Bronstein J; Nawer H; Xu T; Figueroa M; Muntean AG; Hess JL
Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9899-904. PubMed ID: 24958854
[TBL] [Abstract][Full Text] [Related]
58. Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia.
Sharma A; Jyotsana N; Gabdoulline R; Heckl D; Kuchenbauer F; Slany RK; Ganser A; Heuser M
Haematologica; 2020 May; 105(5):1294-1305. PubMed ID: 31413090
[TBL] [Abstract][Full Text] [Related]
59. Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling.
Sharma A; Yun H; Jyotsana N; Chaturvedi A; Schwarzer A; Yung E; Lai CK; Kuchenbauer F; Argiropoulos B; Görlich K; Ganser A; Humphries RK; Heuser M
Leukemia; 2015 Jan; 29(1):157-68. PubMed ID: 24957708
[TBL] [Abstract][Full Text] [Related]
60. c-Met inhibition in a HOXA9/Meis1 model of CN-AML.
Mulgrew NM; Kettyle LM; Ramsey JM; Cull S; Smyth LJ; Mervyn DM; Bijl JJ; Thompson A
Dev Dyn; 2014 Jan; 243(1):172-81. PubMed ID: 24307265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
